AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) Files An 8-K Regulation FD Disclosure
Item7.01.
| Regulation FD. |
From time to time, we conduct meetings with third parties in
which we utilize a corporate slide presentation. A copy of our
current corporate slide presentation is attached as Exhibit 99.1
to this Current Report on Form 8-K and is incorporated herein by
reference. The presentation includes clinical, development,
collaboration and financial updates. We may amend or update this
information at any time and from time to time through another
Current Report on Form 8-K, a later company filing, or other
means.
The information in this Item7.01 and Exhibit 99.1 shall not be
deemed filed for purposes of Section18 of the Securities Exchange
Act of 1934, as amended (the Exchange Act) or otherwise subject
to the liabilities of that section, nor shall it be deemed
incorporated by reference in any filing under the Securities Act
of 1933, as amended, or the Exchange Act, except as expressly set
forth by specific reference in such a filing.
| Item9.01. | Financial Statements and Exhibits. |
(d) The exhibit to this Current Report on Form 8-K is listed in the Exhibit
Index attached hereto.
About AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO)
AVEO Pharmaceuticals, Inc. is a biopharmaceutical company. The Company’s platform delivers insights into cancer and related disease. The Company’s product candidates include Tivozanib, Ficlatuzumab, AV-203 and AV-380. Tivozanib is a selective long half-life vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI) that inhibits over three VEGF receptors. Tivozanib is designed to optimize VEGF blockade while minimizing off-target toxicities. Ficlatuzumab is a Hepatocyte Growth Factor (HGF) inhibitory antibody. AV-203 is an anti-ErbB3 monoclonal antibody with ErbB3 affinity. Its preclinical studies suggest that neuregulin1 (NRG1) levels predict AV-203 antitumor activity in preclinical models. AV-380 is a humanized Immunoglobulin G 1 (IgG1) inhibitory monoclonal antibody. AV-380 targets growth differentiating factor 15 (GDF15). AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) Recent Trading Information
AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) closed its last trading session down -0.007 at 0.622 with 1,207,088 shares trading hands.